文献速递肿瘤 PET/CT核素与放射性配体治疗

人工智能驱动的身体成分监测及其在接受镥-177 PSMA放射配体治疗的mCRPC中的预后作用:一项回顾性单中心分析的启示

AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis.
PubMed 文献 · EJNMMI Res · 2025-08-28

该单中心回顾性分析纳入92例接受[177Lu]Lu-PSMA放射配体治疗的mCRPC患者,采用人工智能PACS集成软件在基线及第二周期后中期 staging 的[68Ga]Ga-PSMA-11 PET/CT上纵向评估身体成分变化。中位OS为16.3个月,多因素分析显示VAT相对变化(HR 0.26)、既往化疗(HR 2.4)、肝转移(HR 2.4)及基线De Ritis比值(HR 1.4)为OS独立预测因子;VAT下降≥20%者中位OS 10.2个月 vs 下降<20%或升高者18.5个月(p=0.008)。

要点

  • VAT相对变化是mCRPC接受RLT患者OS的独立预测因子(HR 0.26,p=0.006)。
  • VAT下降≥20%者中位OS 10.2个月,低于下降<20%或升高者的18.5个月(p=0.008)。
  • 既往化疗、肝转移及较高基线De Ritis比值亦为OS独立预测因子。

核心结论

  • PACS集成的人工智能身体成分监测可检测VAT相对变化,该变化是该RLT人群较短OS的独立预测因子。

研究设计与样本

  • 单中心回顾性分析,纳入2015年9月至2023年12月接受[177Lu]Lu-PSMA RLT的92例mCRPC患者。
  • 所有患者均有基线(首周期RLT前≤6周)及中期分期(第二周期后6-8周)的[68Ga]Ga-PSMA-11 PET/CT以进行纵向身体成分评估。

主要发现

  • 随访期间78例(85%)死亡,中位OS为16.3个月,存活者中位随访时间25.6个月。
  • 1年死亡率为32.6%(95%CI 23.0-42.2%),5年死亡率为92.9%(95%CI 85.8-100.0%)。
  • 多因素回归中,VAT相对变化(HR 0.26;p=0.006)、既往任何类型化疗(HR 2.4;p=0.003)、肝转移(HR 2.4;p=0.018)及较高基线De Ritis比值(HR 1.4;p<0.001)为OS独立预测因子。
  • VAT下降≥20%者中位OS 10.2个月 vs 下降<20%或VAT升高者18.5个月(log-rank检验 p=0.008)。
  • 在另一Cox模型中,VAT变化预测OS(p=0.005)独立于1-2周期RLT后最佳PSA反应(p=0.09),两者无交互作用(p=0.09)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Body composition (BC) analysis is performed to quantify the relative amounts of different body tissues as a measure of physical fitness and tumor cachexia. We hypothesized that relative changes in body composition (BC) parameters, assessed by an artificial intelligence-based, PACS-integrated software, between baseline imaging before the start of radioligand therapy (RLT) and interim staging after two RLT cycles could predict overall survival (OS) in patients with metastatic castration-resistant prostate cancer. METHODS: We conducted a single-center, retrospective analysis of 92 patients with mCRPC undergoing [177Lu]Lu-PSMA RLT between September 2015 and December 2023. All patients had [68 Ga]Ga-PSMA-11 PET/CT at baseline (≤ 6 weeks before the first RLT cycle) and at interim staging (6-8 weeks after the second RLT cycle) allowing for longitudinal BC assessment. RESULTS: During follow-up, 78 patients (85%) died. Median OS was 16.3 months. Median follow-up time in survivors was 25.6 months. The 1 year mortality rate was 32.6% (95%CI 23.0-42.2%) and the 5 year mortality rate was 92.9% (95%CI 85.8-100.0%). In multivariable regression, relative change in visceral adipose tissue (VAT) (HR: 0.26; p = 0.006), previous chemotherapy of any type (HR: 2.4; p = 0.003), the presence of liver metastases (HR: 2.4; p = 0.018) and a higher baseline De Ritis ratio (HR: 1.4; p < 0.001) remained independent predictors of OS. Patients with a higher decrease in VAT (< -20%) had a median OS of 10.2 months versus 18.5 months in patients with a lower VAT decrease or VAT increase (≥ -20%) (log-rank test: p = 0.008). In a separate Cox model, the change in VAT predicted OS (p = 0.005) independent of the best PSA response after 1-2 RLT cycles (p = 0.09), and there was no interaction between the two (p = 0.09). CONCLUSIONS: PACS-Integrated, AI-based BC monitoring detects relative changes in the VAT, Which was an independent predictor of shorter OS in our population of patients undergoing RLT.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ruhwedel T, Rogasch J, Galler M, et al. AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis. EJNMMI Res. 2025. PMID: 40877457. doi:10.1186/s13550-025-01312-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。